Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guilherme Nader

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Therapeutic Advances in Medical Oncology|July 12, 2023
Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatmentGuilherme Nader-Marta, Chiara Molinelli, Véronique Debien, et al.
Ecancermedicalscience|April 18, 2018
Cystic brain metastases in ALK-rearranged non-small cell lung cancerGuilherme Nader Marta, Renata Rodrigues da Cunha Colombo Bonadio, Renata Eiras Martins, et al.
Journal of Cell Science|February 13, 2019
Reconstitution of cell migration at a glanceJuan Manuel Garcia-Arcos, Renaud Chabrier, Mathieu Deygas, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2023
Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysisDiogo Martins-Branco, Guilherme Nader-Marta, Chiara Molinelli, et al.
JCO Global Oncology|November 17, 2020
Trends in Melanoma Mortality in Brazil: A Registry-Based StudyGuilherme Nader Marta, Rodrigo Ramella Munhoz, Monica La Porte Teixeira, et al.
BMC Cancer|December 15, 2018
Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenibLeonardo Gomes da Fonseca, Guilherme Nader Marta, Maria Ignez Freitas Melro Braghiroli, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 2023
Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer: A systematic review and meta-analysisFlavia Jacobs, Chiara Molinelli, Diogo Martins-Branco, et al.
Clinical Breast Cancer|March 21, 2024
The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA TrialVeronique Debien, Elisa Agostinetto, Marco Bruzzone, et al.
Expert Opinion on Investigational Drugs|March 4, 2022
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancerElisa Agostinetto, Agnese Losurdo, Guilherme Nader-Marta, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 27, 2025
PSMA-targeted PET imaging in patients with metastatic triple-negative breast cancer: results of the prospective PRISMA trialMartin Manley, Guilherme Nader-Marta, Ayça Arcay Ozturk, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Therapeutic Advances in Medical Oncology|July 12, 2023
Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatmentGuilherme Nader-Marta, Chiara Molinelli, Véronique Debien, et al.
Ecancermedicalscience|April 18, 2018
Cystic brain metastases in ALK-rearranged non-small cell lung cancerGuilherme Nader Marta, Renata Rodrigues da Cunha Colombo Bonadio, Renata Eiras Martins, et al.
Journal of Cell Science|February 13, 2019
Reconstitution of cell migration at a glanceJuan Manuel Garcia-Arcos, Renaud Chabrier, Mathieu Deygas, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2023
Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysisDiogo Martins-Branco, Guilherme Nader-Marta, Chiara Molinelli, et al.
JCO Global Oncology|November 17, 2020
Trends in Melanoma Mortality in Brazil: A Registry-Based StudyGuilherme Nader Marta, Rodrigo Ramella Munhoz, Monica La Porte Teixeira, et al.
BMC Cancer|December 15, 2018
Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenibLeonardo Gomes da Fonseca, Guilherme Nader Marta, Maria Ignez Freitas Melro Braghiroli, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 2023
Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer: A systematic review and meta-analysisFlavia Jacobs, Chiara Molinelli, Diogo Martins-Branco, et al.
Clinical Breast Cancer|March 21, 2024
The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA TrialVeronique Debien, Elisa Agostinetto, Marco Bruzzone, et al.
Expert Opinion on Investigational Drugs|March 4, 2022
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancerElisa Agostinetto, Agnese Losurdo, Guilherme Nader-Marta, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 27, 2025
PSMA-targeted PET imaging in patients with metastatic triple-negative breast cancer: results of the prospective PRISMA trialMartin Manley, Guilherme Nader-Marta, Ayça Arcay Ozturk, et al.
Pageof 5